Literature DB >> 11426788

Off-pump combined coronary artery bypass grafting and left upper lobectomy through left posterolateral thoracotomy.

A A Ahmed1, M A Sarsam.   

Abstract

A 61-year-old man with angina had a lesion in the left upper lobe of his lung on chest roentgenogram. Coronary angiography revealed a dominant circumflex lesion. Combined coronary artery bypass grafting (CABG) and left upper lobectomy was performed through left posterolateral thoracotomy without the use of cardiopulmonary bypass. Off-pump CABG abolishes the complications of cardiopulmonary bypass, while posterolateral thoracotomy provides a direct access to the circumflex vessels and is ideal for lung resection.

Entities:  

Mesh:

Year:  2001        PMID: 11426788     DOI: 10.1016/s0003-4975(00)02410-3

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Coronary artery bypass grafting with concomitant resection for carcinoma of lung.

Authors:  Yangyang Zhang; Yanhu Wu; Biao Yuan; Xiang Liu; Sheng Zhao; Zhi Li; Yu Xia
Journal:  J Biomed Res       Date:  2010-01

2.  T-Bar Utilization for Concomitant Coronary Artery Bypass Graft Operation and Left Upper Lobectomy.

Authors:  Fotios Mitropoulos; Meletios A Kanakis; Anastasios Apostolou; Andrew Chatzis; Constantinos Contrafouris; Christos Apostolidis; Achilleas Lioulias
Journal:  Case Rep Surg       Date:  2016-03-02

Review 3.  Anesthetic management of off-pump simultaneous coronary artery bypass grafting and lobectomy: Case report and literature review.

Authors:  Xian Zhao; Yuhong Li; Hai-Ying Kong; Lin Zhang; Xiao-Hong Wen
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

4.  Comparison of perioperative characteristics and prognostic performance in patients with pulmonary lobectomy in early or later period after percutaneous coronary intervention.

Authors:  Tianyang Yun; Yue Tang; Bo Yang; Ke Li; Tao Liang; Dongtao Yin; Yang Liu
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.